Profile data is unavailable for this security.
About the company
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
- Revenue in USD (TTM)22.18m
- Net income in USD-104.32m
- Incorporated2000
- Employees345.00
- LocationCellectis SA8, rue de la Croix JarryPARIS 75013FranceFRA
- Phone+33 181691600
- Fax+33 181691606
- Websitehttp://www.cellectis.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kronos Bio Inc | 0.00 | -163.76m | 97.87m | 101.00 | -- | 0.3627 | -- | -- | -2.93 | -2.93 | 0.00 | 4.74 | 0.00 | -- | -- | 0.00 | -42.80 | -- | -44.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -70.82 | -- | -- | -- |
| Ikena Oncology Inc | 30.39m | -51.87m | 99.35m | 67.00 | -- | 0.6257 | -- | 3.27 | -1.43 | -1.43 | 0.8413 | 4.38 | 0.1344 | -- | -- | 453,507.50 | -22.94 | -- | -26.16 | -- | -- | -- | -170.71 | -- | -- | -- | 0.00 | -- | 237.01 | -- | 22.91 | -- | -- | -- |
| Portage Biotech Inc | 0.00 | -13.51m | 99.66m | 6.00 | -- | 0.5547 | -- | -- | -0.9978 | -0.9978 | 0.00 | 10.53 | 0.00 | -- | -- | 0.00 | -7.61 | 11.61 | -8.61 | 15.79 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.55 | -- | -- | -- |
| Shattuck Labs Inc | 30.34m | -68.69m | 100.04m | 85.00 | -- | 0.5017 | -- | 3.30 | -1.62 | -1.62 | 0.7164 | 4.70 | 0.1137 | -- | -- | 356,941.20 | -25.75 | -- | -27.78 | -- | -- | -- | -226.39 | -- | -- | -50.69 | 0.00 | -- | 202.16 | -- | -22.87 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -100.25m | 100.33m | 73.00 | -- | 0.4566 | -- | -- | -2.51 | -2.51 | 0.00 | 5.43 | 0.00 | -- | -- | 0.00 | -37.01 | -- | -38.53 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -196.36 | -- | -- | -- |
| Imara Inc | 0.00 | -45.02m | 100.94m | 41.00 | -- | 1.76 | -- | -- | -1.71 | -1.71 | 0.00 | 2.18 | 0.00 | -- | -- | 0.00 | -54.19 | -- | -57.30 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.40 | -- | -- | -- |
| ProQR Therapeutics NV | 4.15m | -75.95m | 101.44m | 181.00 | -- | 1.55 | -- | 24.43 | -1.06 | -1.06 | 0.0582 | 0.9154 | 0.0248 | -- | -- | 22,937.39 | -45.25 | -47.53 | -55.97 | -53.01 | -- | -- | -1,824.08 | -1,168.37 | -- | -- | 0.2561 | -- | -74.64 | 5.57 | -32.33 | -- | -28.21 | -- |
| Cellectis SA (ADR) | 22.18m | -104.32m | 101.56m | 345.00 | -- | 0.7472 | -- | 4.58 | -2.29 | -2.29 | 0.4875 | 3.00 | 0.0641 | -- | 38.54 | 64,289.86 | -32.80 | -24.90 | -40.80 | -30.71 | -98.70 | -29.56 | -511.97 | -232.72 | -- | -- | 0.372 | -- | -18.66 | 3.51 | -40.86 | -- | -18.03 | -- |
| Alzamend Neuro Inc | 0.00 | -13.08m | 102.17m | 4.00 | -- | 9.14 | -- | -- | -0.141 | -0.141 | 0.00 | 0.1171 | 0.00 | -- | -- | 0.00 | -90.11 | -- | -98.61 | -- | -- | -- | -- | -- | -- | -379.00 | 0.00 | -- | -- | -- | -144.96 | -- | -- | -- |
| Capricor Therapeutics Inc | 1.59m | -27.49m | 102.73m | 48.00 | -- | 6.52 | -- | 64.55 | -1.13 | -1.13 | 0.0655 | 0.6245 | 0.0328 | -- | 4.37 | 33,157.71 | -56.66 | -53.39 | -77.60 | -60.10 | -- | -- | -1,727.17 | -916.96 | -- | -- | 0.1796 | -- | -21.06 | -42.80 | -46.61 | -- | 43.92 | -- |
| Eyepoint Pharmaceuticals Inc | 42.42m | -78.23m | 103.27m | 122.00 | -- | 0.7572 | -- | 2.43 | -2.17 | -2.17 | 1.17 | 4.00 | 0.2182 | 1.96 | 2.46 | 347,663.90 | -40.25 | -- | -46.77 | -- | 81.26 | -- | -184.45 | -- | 5.50 | -27.12 | 0.2259 | -- | 7.27 | -- | -28.69 | -- | -- | -- |
| Opiant Pharmaceuticals Inc | 22.34m | -33.09m | 104.54m | 37.00 | -- | 5.10 | -- | 4.68 | -6.56 | -6.56 | 4.02 | 3.97 | 0.4028 | -- | 2.89 | 603,740.00 | -59.66 | -- | -68.55 | -- | 82.70 | -- | -148.12 | -- | -- | -21.51 | 0.4016 | -- | 61.30 | -- | 261.64 | -- | -- | -- |
Data as of Dec 08 2022. Currency figures normalised to Cellectis SA's reporting currency: US Dollar USD
18.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Long Focus Capital Management LLCas of 30 Sep 2022 | 2.68m | 5.90% |
| Credit Suisse Asset Management (Schweiz) AGas of 30 Sep 2022 | 1.44m | 3.16% |
| Principal Global Investors LLCas of 30 Sep 2022 | 1.34m | 2.95% |
| Baillie Gifford & Co.as of 30 Sep 2022 | 788.84k | 1.74% |
| Millennium Management LLCas of 30 Sep 2022 | 573.84k | 1.26% |
| Capital Research & Management Co. (International Investors)as of 30 Sep 2022 | 448.80k | 0.99% |
| Jane Street Capital LLCas of 30 Sep 2022 | 343.89k | 0.76% |
| D. E. Shaw & Co. LPas of 30 Sep 2022 | 278.33k | 0.61% |
| BlackRock Fund Advisorsas of 30 Sep 2022 | 272.75k | 0.60% |
| SSgA Funds Management, Inc.as of 30 Sep 2022 | 262.37k | 0.58% |
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
